Herbal & Natural Products

Herbal and natural products are a growing category with both clinical interest and regulatory challenges. The session covers berberine cardiometabolic evidence ('nature's Ozempic' marketing), curcumin bioavailability formulations (Meriva, Theracurmin, BCM-95), St. John's wort drug interactions, natural-product quality standards (USP, GMP, ISO 17025), the FDA botanical drug review pathway, and adaptogens (ashwagandha, rhodiola). Discussion addresses cannabis/CBD products and regulation, mushroom-based supplements (lion's mane, reishi), kratom regulatory status, supplement vs drug claim regulation globally, and emerging clinical trials of botanical products.